FGF9 and coronary artery disorder: HAS2 knockdown can alleviate I/R-induced cell damage, reduce cell apoptosis, and enhance cell viability by modulating the expression of FGF9. Importantly, Tan IIA can inhibit the production of inflammatory cytokines and attenuate oxidative stress by modulating the expression of FGF9. These results demonstrate the therapeutic potential of using Tan IIA to target the HAS2/FGF9 axis to reduce myocardial damage, offering a viable approach to the treatment of CHD.